title: [Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
abstract: BACKGROUND
  In July 2008, cetuximab treatment for unresectable advanced or recurrent colorectal cancer was approved in Japan, but there have been few reports on this therapy in Japan.
  
  
  OBJECTIVE
  We retrospectively analyzed the efficacy and safety of cetuximab(Cmab)+irinotecan(CPT-11)for unresectable advanced or recurrent colorectal cancer from October 2008 to April 2010 at 5 centers in the Kanagawa region.
  
  
  METHODS
  The number of patients enrolled was 38, all of whom were treated after second-line therapy.
  
  
  RESULTS
  The RR was 24%. DCR was 68%. TTF was 105 days and OS was 242 days.
  
  
  CONCLUSIONS
  At 5 centers, Cmab+CPT-11 was an effective and safe treatment after second-line therapy.
authors.affiliation: Dept. of Surgery, Showa University Fujigaoka Hospital, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Soda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nemoto
authors.forename: Sotaro
authors.initials: S
authors.lastname: Akatsuka
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Arioka
authors.forename: Ken
authors.initials: K
authors.lastname: Shimada
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ito
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Takinishi
authors.forename: Mizutomo
authors.initials: M
authors.lastname: Egawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagashima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kenmochi
authors.forename: Toru
authors.initials: T
authors.lastname: Sasaki
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Azuma
authors.forename: Wasaburo
authors.initials: W
authors.lastname: Koizumi
authors.forename: Kenji
authors.initials: K
authors.lastname: Hibi
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D012008:Recurrence; D012189:Retrospective Studies; D018631:ras Proteins / Q000235:genetics
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002166:Camptothecin